P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (Anti-Tigit) in Patients with PD-L1‒Positive Metastatic NSCLC

Vibostolimab (MK-7684) is a humanized monoclonal antibody that binds to the T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), blocking the interaction between TIGIT and its ligands, CD112 and CD155. Pembrolizumab, a monoclonal antibody against the PD-1 receptor, significantly improves OS versus chemotherapy in patients with previously treated and previously untreated advanced non-small-cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥1%. In the first-in-human study (NCT02964013), the combination of vibostolimab plus pembrolizumab had a manageable safety profile and showed promising antitumor activity in patients with advanced NSCLC who were naive to anti-PD-(L)1 therapy; ORR was 31% and 25% in patients with PD-L1 TPS ≥1% and <1%, respectively.